MX2009002054A - Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. - Google Patents
Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.Info
- Publication number
- MX2009002054A MX2009002054A MX2009002054A MX2009002054A MX2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A
- Authority
- MX
- Mexico
- Prior art keywords
- angiogenesis
- associated diseases
- methods
- treating
- composition
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 5
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010025421 Macule Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960001338 colchicine Drugs 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical class C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona métodos para inhibir la angiogénesis en un individuo mediante la administración de una composición (como una proteína contenida en la composición) que comprende el dímero de colchicina o tiocolchicina. La composición está presente en una cantidad efectiva para la inhibición de angiogénesis, pero en algunas modalidades es insuficiente para inducir una citotoxicidad significativa en el individuo. Los métodos descritos aquí son útiles para el tratamiento contra enfermedades asociadas con la angiogénesis, como degeneración macular relacionada con la edad, retinopatía diabética, artritis reumática, psoriasis y cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2006/034365 WO2008027055A1 (en) | 2006-08-31 | 2006-08-31 | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009002054A true MX2009002054A (es) | 2009-05-01 |
Family
ID=37763804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009002054A MX2009002054A (es) | 2006-08-31 | 2006-08-31 | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2056812A1 (es) |
| JP (1) | JP2010502603A (es) |
| CN (1) | CN101568332A (es) |
| AU (1) | AU2006347740A1 (es) |
| BR (1) | BRPI0622006A2 (es) |
| CA (1) | CA2662140A1 (es) |
| IL (1) | IL197276A0 (es) |
| MX (1) | MX2009002054A (es) |
| WO (1) | WO2008027055A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| CA3201293A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| TW201012473A (en) * | 2008-09-22 | 2010-04-01 | Tty Biopharm Co Ltd | Composition of inhibiting pathological angiogenesis |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| CN102802658A (zh) * | 2009-12-21 | 2012-11-28 | 台湾东洋药品工业股份有限公司 | 白细胞衍生趋化因子2于肿瘤细胞内降低肝细胞生长因子受体的磷酸化相关的方法与组合物 |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| US20140228299A1 (en) * | 2011-09-20 | 2014-08-14 | National University Corporation Tokyo Medical And Dental University | Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1318401B1 (it) * | 2000-03-17 | 2003-08-25 | Indena Spa | Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono. |
| NZ541142A (en) * | 2002-12-09 | 2008-07-31 | Abraxis Bioscience Inc | Compositions and methods of delivery of pharmacological agents |
| DK1585548T3 (en) * | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US6825236B2 (en) * | 2003-04-14 | 2004-11-30 | California Pacific Medical Center | Colchicine derivatives |
| ITMI20040164A1 (it) * | 2004-02-03 | 2004-05-03 | Indena Spa | Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono |
| SG166775A1 (en) * | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
-
2006
- 2006-08-31 MX MX2009002054A patent/MX2009002054A/es not_active Application Discontinuation
- 2006-08-31 JP JP2009526583A patent/JP2010502603A/ja active Pending
- 2006-08-31 BR BRPI0622006-1A patent/BRPI0622006A2/pt not_active Application Discontinuation
- 2006-08-31 CA CA002662140A patent/CA2662140A1/en not_active Abandoned
- 2006-08-31 WO PCT/US2006/034365 patent/WO2008027055A1/en not_active Ceased
- 2006-08-31 AU AU2006347740A patent/AU2006347740A1/en not_active Abandoned
- 2006-08-31 EP EP06802881A patent/EP2056812A1/en not_active Withdrawn
- 2006-08-31 CN CNA2006800561122A patent/CN101568332A/zh active Pending
-
2009
- 2009-02-26 IL IL197276A patent/IL197276A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL197276A0 (en) | 2009-12-24 |
| CN101568332A (zh) | 2009-10-28 |
| EP2056812A1 (en) | 2009-05-13 |
| CA2662140A1 (en) | 2008-03-06 |
| BRPI0622006A2 (pt) | 2011-12-20 |
| JP2010502603A (ja) | 2010-01-28 |
| WO2008027055A1 (en) | 2008-03-06 |
| AU2006347740A1 (en) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009002054A (es) | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. | |
| MX2010014233A (es) | Compuestos quimicos 251. | |
| MX2024000208A (es) | Restos de administracion terapeutica novedosos y usos de estos. | |
| MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| MY148246A (en) | Bicyclic amides as kinase inhibitors | |
| BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
| IN2012DN02018A (es) | ||
| IN2014MN00139A (es) | ||
| EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| MX383644B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| TN2012000143A1 (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
| AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
| BRPI0610090A2 (pt) | terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas | |
| ATE401088T1 (de) | Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs | |
| MY148893A (en) | Combination of an hdac inhibitor and an antimetabolite | |
| BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
| UY29161A1 (es) | Nuevos heterociclos | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| BRPI0509667A (pt) | azaquinazolinas substituìdas com eficácia antiviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |